Adamas announces two presentations for the american academy of neurology 73rd annual meeting

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the american academy of neurology (aan) 73rd annual meeting. one of the presentations will focus on gocovri® (amantadine) extended-release capsules, the first and only fda-approved medicine indicated for the treatment of dyskinesi
ADMS Ratings Summary
ADMS Quant Ranking